Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
Andreef, M.
Faderl, S.
Wright, J.
Zhang, W.
Konopleva, M.
Verstovsek, S.
Borthakur, G.
Cortes, J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7018
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Sorafenib (BAY 43-9006): Preliminary antitumor activity in metastatic renal cell carcinoma in a Phase II randomized discontinuation trial
    Eisen, T
    ANNALS OF ONCOLOGY, 2005, 16 : 17 - 17
  • [32] First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment
    Maroto-Rey, P.
    Bellmunt, J.
    Trigo, J. M.
    Guillem, V.
    Lopez-Martin, J. A.
    Carles, J.
    Anton-Torres, A.
    Urruticoechea, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer
    Siu, LL
    Takimoto, CH
    Awada, A
    Moore, MJ
    Piccart, M
    Poulin-Costello, M
    Lathia, C
    Petrenciuc, O
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
  • [34] A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC).
    Adjei, AA
    Mandrekar, S
    Marks, RS
    Hanson, LJ
    Aranguren, D
    Jett, JR
    Simantov, R
    Schwartz, B
    Croghan, GA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [35] Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors
    Figer, A.
    Moscovici, M.
    Bulocinic, S.
    Radu, P.
    Atsmon, J.
    Shmuely, E.
    Laba, O.
    Gadish, D.
    Brendel, E.
    Schwartz, B.
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 88
  • [36] Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Kadia, Tapan M.
    Cortes, Jorge E.
    Borthakur, Gautam
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    Koller, Charles Asa
    Dellasala, Sara E.
    Pierce, Sherry A.
    Burton, Elizabeth M.
    Verstovsek, Srdan
    BLOOD, 2012, 120 (21)
  • [37] A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
    Srkalovic, Gordan
    Hussein, Mohamad A.
    Hoering, Antje
    Zonder, Jeffrey A.
    Popplewell, Leslie L.
    Trivedi, Harsha
    Mazzoni, Sandy
    Sexton, Rachel
    Orlowski, Robert Z.
    Barlogie, Bart
    CANCER MEDICINE, 2014, 3 (05): : 1275 - 1283
  • [38] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Kadia, Tapan
    Ning, Jing
    Gonzalez, Graciela Nogueras
    Pierce, Sherry
    Kelly, Mary
    Zhang, Weiguo
    Gombos, Dan
    Kornblau, Steven
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Andreeff, Michael
    BLOOD, 2017, 130
  • [39] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Jabbour, Elias
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Pierce, Sherry
    Gombos, Dan
    Komblau, Steven
    Konopleva, Marina
    Kelly, Mary
    Borthakur, Gautam
    Zhang, Weiguo
    Cortes, Jorge
    Kantarjian, Hagop
    Andreeffl, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
  • [40] Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.
    Andreeff, Michael
    Borthakur, Gautam
    Zeng, Zhihong
    Kelly, Mary A.
    Wang, Rui-Yu
    McQueen, Teresa J.
    Qiu, Yihua
    Mak, Duncan
    Burger, Jan Andreas
    Daver, Naval Guastad
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Jabbour, Elias
    Pierce, Sherry
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    O'Brien, Susan Mary
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345